BR112022010941A2 - Agente terapêutico, complexo proteico, métodos para promover a fuga da lise mediada por célula exterminadora natural e por célula t, para deter posicionalmente cd45 na superfície de uma célula que expressa cd45, para produzir uma célula xenogênica, para prevenir a rejeição de transplante de órgão sólido ou organoide e para tratar câncer, célula não autóloga, proteína recombinante, célula, primeira célula citotóxica, célula citotóxica, enxerto tratado, e, uso de um engajador - Google Patents
Agente terapêutico, complexo proteico, métodos para promover a fuga da lise mediada por célula exterminadora natural e por célula t, para deter posicionalmente cd45 na superfície de uma célula que expressa cd45, para produzir uma célula xenogênica, para prevenir a rejeição de transplante de órgão sólido ou organoide e para tratar câncer, célula não autóloga, proteína recombinante, célula, primeira célula citotóxica, célula citotóxica, enxerto tratado, e, uso de um engajadorInfo
- Publication number
- BR112022010941A2 BR112022010941A2 BR112022010941A BR112022010941A BR112022010941A2 BR 112022010941 A2 BR112022010941 A2 BR 112022010941A2 BR 112022010941 A BR112022010941 A BR 112022010941A BR 112022010941 A BR112022010941 A BR 112022010941A BR 112022010941 A2 BR112022010941 A2 BR 112022010941A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- cytotoxic
- methods
- organoid
- expresses
- Prior art date
Links
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 title abstract 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 5
- 229940124597 therapeutic agent Drugs 0.000 title abstract 5
- 231100000433 cytotoxic Toxicity 0.000 title abstract 4
- 230000001472 cytotoxic effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000009089 cytolysis Effects 0.000 title abstract 2
- 210000000056 organ Anatomy 0.000 title abstract 2
- 210000002220 organoid Anatomy 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 238000002054 transplantation Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 9
- 101150082208 DIABLO gene Proteins 0.000 abstract 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 abstract 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 abstract 1
- 101000606506 Homo sapiens Receptor-type tyrosine-protein phosphatase eta Proteins 0.000 abstract 1
- 102100039564 Leukosialin Human genes 0.000 abstract 1
- 102100039808 Receptor-type tyrosine-protein phosphatase eta Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000030609 dephosphorylation Effects 0.000 abstract 1
- 238000006209 dephosphorylation reaction Methods 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 210000000428 immunological synapse Anatomy 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement Of Force In General (AREA)
- Biomedical Technology (AREA)
Abstract
AGENTE TERAPÊUTICO, COMPLEXO PROTEICO, MÉTODOS PARA PROMOVER A FUGA DA LISE MEDIADA POR CÉLULA EXTERMINADORA NATURAL E POR CÉLULA T, PARA DETER POSICIONALMENTE CD45 NA SUPERFÍCIE DE UMA CÉLULA QUE EXPRESSA CD45, PARA PRODUZIR UMA CÉLULA XENOGÊNICA, PARA PREVENIR A REJEIÇÃO DE TRANSPLANTE DE ÓRGÃO SÓLIDO OU ORGANOIDE E PARA TRATAR CÂNCER, CÉLULA NÃO AUTÓLOGA, PROTEÍNA RECOMBINANTE, CÉLULA, PRIMEIRA CÉLULA CITOTÓXICA, CÉLULA CITOTÓXICA, ENXERTO TRATADO, E, USO DE UM ENGAJADOR. Agentes terapêuticos capazes de deter proteínas volumosas, como CD45, CD148 e CD43 no meio da interface celular entre uma célula de enxerto e uma célula efetora hospedeira positiva para CD45 (como uma célula T, célula NK, célula B ou célula dendrítica) são descritos, assim como métodos para seu uso e produtos feitos com tais agentes terapêuticos. Os agentes terapêuticos previnem ou inibem a formação de sinapses imunológicas funcionais (incluindo SMAC fisiológica). Eles também resultam em desfosforilação contínua das vias de transdução de sinal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943807P | 2019-12-05 | 2019-12-05 | |
| PCT/US2020/063682 WO2021113853A1 (en) | 2019-12-05 | 2020-12-07 | Modulators of the immune escape mechanism for universal cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010941A2 true BR112022010941A2 (pt) | 2022-09-06 |
Family
ID=76222058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010941A BR112022010941A2 (pt) | 2019-12-05 | 2020-12-07 | Agente terapêutico, complexo proteico, métodos para promover a fuga da lise mediada por célula exterminadora natural e por célula t, para deter posicionalmente cd45 na superfície de uma célula que expressa cd45, para produzir uma célula xenogênica, para prevenir a rejeição de transplante de órgão sólido ou organoide e para tratar câncer, célula não autóloga, proteína recombinante, célula, primeira célula citotóxica, célula citotóxica, enxerto tratado, e, uso de um engajador |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230272035A1 (pt) |
| EP (1) | EP4069748A4 (pt) |
| JP (1) | JP2023504884A (pt) |
| KR (1) | KR20220137882A (pt) |
| CN (1) | CN115551887A (pt) |
| AU (1) | AU2020397189A1 (pt) |
| BR (1) | BR112022010941A2 (pt) |
| CA (1) | CA3160759A1 (pt) |
| IL (1) | IL293552A (pt) |
| MX (1) | MX2022006841A (pt) |
| WO (1) | WO2021113853A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6024957A (en) * | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
| AU2005250341A1 (en) * | 2004-04-23 | 2005-12-15 | Amgen Inc. | Antibodies to angiogenesis inhibiting domains of CD148 |
| PL2222706T5 (pl) * | 2007-12-14 | 2017-09-29 | Novo Nordisk As | Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania |
| US20120020987A1 (en) * | 2010-07-26 | 2012-01-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | MHC-Less cells |
| EP2502631A1 (en) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
| BR112014019611A2 (pt) * | 2012-02-07 | 2017-06-27 | Innate Pharma | agentes de ligação mica |
| EP3241897B1 (en) * | 2013-03-07 | 2018-10-03 | Baylor College of Medicine | Targeting cd138 in cancer |
| RU2743188C2 (ru) * | 2015-04-23 | 2021-02-16 | Хемалоджикс Пти. Лтд. | Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения |
| US20190002912A1 (en) * | 2015-06-19 | 2019-01-03 | Massachusetts Institute Of Technology | Tumor immunotherapy |
| CA2990177A1 (en) * | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| JP7108551B2 (ja) * | 2016-03-19 | 2022-07-28 | エクスマ バイオテック コーポレイション | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| US10875919B2 (en) * | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
| EP4353750A2 (en) * | 2016-06-24 | 2024-04-17 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
| EP3648786A4 (en) * | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES |
| JP2019122373A (ja) * | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | 抗ｐｄ−１抗体及び治療方法 |
| MX2020010753A (es) * | 2018-04-10 | 2021-01-29 | Amgen Inc | Receptores quimericos de dll3 y metodos para su uso. |
| AU2019269628A1 (en) * | 2018-05-17 | 2020-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
-
2020
- 2020-12-07 IL IL293552A patent/IL293552A/en unknown
- 2020-12-07 US US17/782,509 patent/US20230272035A1/en active Pending
- 2020-12-07 MX MX2022006841A patent/MX2022006841A/es unknown
- 2020-12-07 EP EP20896046.8A patent/EP4069748A4/en active Pending
- 2020-12-07 KR KR1020227022994A patent/KR20220137882A/ko unknown
- 2020-12-07 JP JP2022534315A patent/JP2023504884A/ja active Pending
- 2020-12-07 AU AU2020397189A patent/AU2020397189A1/en active Pending
- 2020-12-07 CN CN202080095579.8A patent/CN115551887A/zh active Pending
- 2020-12-07 CA CA3160759A patent/CA3160759A1/en active Pending
- 2020-12-07 BR BR112022010941A patent/BR112022010941A2/pt unknown
- 2020-12-07 WO PCT/US2020/063682 patent/WO2021113853A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069748A4 (en) | 2023-11-15 |
| JP2023504884A (ja) | 2023-02-07 |
| AU2020397189A1 (en) | 2022-07-14 |
| IL293552A (en) | 2022-08-01 |
| KR20220137882A (ko) | 2022-10-12 |
| CA3160759A1 (en) | 2021-06-10 |
| WO2021113853A1 (en) | 2021-06-10 |
| EP4069748A1 (en) | 2022-10-12 |
| CN115551887A (zh) | 2022-12-30 |
| MX2022006841A (es) | 2022-09-19 |
| US20230272035A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schenkel et al. | Cutting edge: resident memory CD8 T cells occupy frontline niches in secondary lymphoid organs | |
| Amorim et al. | The artificial ovary: current status and future perspectives | |
| Yoshida et al. | Peripheral blood mononuclear cells enhance the anabolic effects of platelet‐rich plasma on anterior cruciate ligament fibroblasts | |
| BR112022010941A2 (pt) | Agente terapêutico, complexo proteico, métodos para promover a fuga da lise mediada por célula exterminadora natural e por célula t, para deter posicionalmente cd45 na superfície de uma célula que expressa cd45, para produzir uma célula xenogênica, para prevenir a rejeição de transplante de órgão sólido ou organoide e para tratar câncer, célula não autóloga, proteína recombinante, célula, primeira célula citotóxica, célula citotóxica, enxerto tratado, e, uso de um engajador | |
| Haque et al. | Giant cell tumor of bone: a neoplasm or a reactive condition? | |
| Paebst et al. | Comparative immunophenotyping of equine multipotent mesenchymal stromal cells: an approach toward a standardized definition | |
| US8324449B2 (en) | Acellular tissue matrices made from alpha-1,3-galactose-deficient tissue | |
| BR9809791A (pt) | Compostos de fosfato de aminoalquil glucosamina e seu uso como auxiliares e imuno efetores | |
| Prantl et al. | Serologic and histologic findings in patients with capsular contracture after breast augmentation with smooth silicone gel implants: is serum hyaluronan a potential predictor? | |
| Garbe et al. | Regulation of bone mass and osteoclast function depend on the F‐actin modulator SWAP‐70 | |
| Maeda | Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses | |
| CY1108459T1 (el) | Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων | |
| BR112021024822A2 (pt) | Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência | |
| Wagner et al. | Diminished bone regeneration after debridement of posttraumatic osteomyelitis is accompanied by altered cytokine levels, elevated B cell activity, and increased osteoclast activity | |
| Sridharan et al. | Hydroxyapatite particle shape and size influence MSC osteogenesis by directing the macrophage phenotype in collagen-hydroxyapatite scaffolds | |
| Svahn et al. | Dietary polyunsaturated fatty acids promote neutrophil accumulation in the spleen by altering chemotaxis and delaying cell death | |
| Rodriguez et al. | In vitro characterization of MG‐63 osteoblast‐like cells cultured on organic‐inorganic lyophilized gelatin sponges for early bone healing | |
| KR20160123901A (ko) | 생체적합성 각막 생성방법 및 생체적합성 조직 탈세포 처리 조성물 | |
| AR018489A1 (es) | Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma | |
| Kocher et al. | Stem cells and cardiac regeneration | |
| Adamiak et al. | Purinergic signaling regulates mobilization of hematopoietic stem cells | |
| Fefer et al. | Abolition of neonatally-induced homograft tolerance in mice by sublethal x-irradiation | |
| Clark | Systemic cancer and the metastatic process | |
| Naylor et al. | Immunopharmacology of thymosin α1 and cytokine synergy | |
| Bengtsson et al. | Sulfatide-induced L-selectin activation generates intracellular oxygen radicals in human neutrophils: modulation by extracellular adenosine |